

**PLA2G1B Antibody (C-term) Blocking Peptide**  
**Synthetic peptide**  
**Catalog # BP4878b****Specification**

---

**PLA2G1B Antibody (C-term) Blocking Peptide - Product Information**Primary Accession [P04054](#)**PLA2G1B Antibody (C-term) Blocking Peptide - Additional Information****Gene ID** 5319**Other Names**

Phospholipase A2, Group IB phospholipase A2, Phosphatidylcholine 2-acylhydrolase 1B, PLA2G1B, PLA2, PLA2A, PPLA2

**Format**

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

**Storage**

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

**Precautions**

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

**PLA2G1B Antibody (C-term) Blocking Peptide - Protein Information****Name** PLA2G1B**Synonyms** PLA2, PLA2A, PPLA2**Function**

Secretory calcium-dependent phospholipase A2 that primarily targets dietary phospholipids in the intestinal tract (PubMed: [1420353](http://www.uniprot.org/citations/1420353), PubMed: [10681567](http://www.uniprot.org/citations/10681567), PubMed: [17603006](http://www.uniprot.org/citations/17603006)). Hydrolyzes the ester bond of the fatty acyl group attached at sn-2 position of phospholipids (phospholipase A2 activity) with preference for phosphatidylethanolamines and phosphatidylglycerols over phosphatidylcholines (PubMed: [1420353](http://www.uniprot.org/citations/1420353), PubMed: [10681567](http://www.uniprot.org/citations/10681567), PubMed: [17603006](http://www.uniprot.org/citations/17603006)). May play a role in the biosynthesis of N-acyl ethanolamines that regulate energy metabolism and inflammation in the intestinal tract. Hydrolyzes N-acyl phosphatidylethanolamines to N-acyl lysophosphatidylethanolamines, which are further cleaved by a lysophospholipase D to release N-acyl ethanolamines (By similarity). May act in an autocrine and paracrine manner (PubMed: [7721806](http://www.uniprot.org/citations/7721806), PubMed: [7721806](http://www.uniprot.org/citations/7721806)).

<http://www.uniprot.org/citations/25335547>). Upon binding to the PLA2R1 receptor can regulate podocyte survival and glomerular homeostasis (PubMed:<http://www.uniprot.org/citations/25335547>). Has anti-helminth activity in a process regulated by gut microbiota. Upon helminth infection of intestinal epithelia, directly affects phosphatidylethanolamine contents in the membrane of helminth larvae, likely controlling an array of phospholipid-mediated cellular processes such as membrane fusion and cell division while providing for better immune recognition, ultimately reducing larvae integrity and infectivity (By similarity).

**Cellular Location**

Secreted. Note=Secreted from pancreatic acinar cells in its inactive form

**Tissue Location**

Selectively expressed in pancreas, lung, liver and kidney. Also detected at lower levels in ovary and testis

**PLA2G1B Antibody (C-term) Blocking Peptide - Protocols**

Provided below are standard protocols that you may find useful for product applications.

- [Blocking Peptides](#)

**PLA2G1B Antibody (C-term) Blocking Peptide - Images****PLA2G1B Antibody (C-term) Blocking Peptide - Background**

PLA2G1B catalyzes the release of fatty acids from glycerol-3-phosphocholines. The best known varieties are the digestive enzymes secreted as zymogens by the pancreas of mammals. Sequences of pancreatic PLA2 enzymes from a variety of mammals have been reported. One striking feature of these enzymes is their close homology to venom phospholipases of snakes. Other forms of PLA2 have been isolated from brain, liver, lung, spleen, intestine, macrophages, leukocytes, erythrocytes, inflammatory exudates, chondrocytes, and platelets

**PLA2G1B Antibody (C-term) Blocking Peptide - References**

Xu, W., et al. J. Biol. Chem. 284(24):16659-16666(2009) Han, C., et al. J. Cell. Biochem. 105(2):534-545(2008) Kao, W.T., et al. Lipids Health Dis 7, 20 (2008)